Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Stock

Equities

6990

CNE1000062J1

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. 04:08:11 2024-05-08 am EDT 5-day change 1st Jan Change
165 HKD +2.48% Intraday chart for Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. -1.96% +60.35%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 1.16B 161M 1.26B Sales 2025 * 1.52B 211M 1.65B Capitalization 33.43B 4.63B 36.18B
Net income 2024 * -550M -76.14M -595M Net income 2025 * -603M -83.48M -653M EV / Sales 2024 * 28.3 x
Net cash position 2024 * 575M 79.57M 622M Net cash position 2025 * 774M 107M 837M EV / Sales 2025 * 21.4 x
P/E ratio 2024 *
-58 x
P/E ratio 2025 *
-53.1 x
Employees 1,446
Yield 2024 *
-
Yield 2025 *
-
Free-Float 55.25%
More Fundamentals * Assessed data
Dynamic Chart
Sichuan Kelun-biotech Biopharmaceutical to Place 3.6 Million Shares; Inks Subscription Deal for 4.4 Million Shares MT
Kelun-Biotech's Lung Cancer Drug Advances to Phase 2 Trials in US; Shares Up 8% MT
Sichuan Kelun-Biotech Buys Structured Deposits Worth 680 Million Yuan MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Study Results for Core Product Scituzumab Turumotecan (SAC-TMT) at AACR Annual Meeting 2024 CI
Kelun-Biotech Shrinks Loss by 7% in 2023 MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
China Healthcare Stocks Rally on Hopes for Government Support DJ
China Grants Breakthrough Therapy Designation for Kelun-Biotech's Breast Cancer Treatment MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Its Core Product SKB264 (MK-2870) Granted Breakthrough Therapy Designation for First-Line Treatment of Unresectable Locally Advanced, Recurring or Metastatic Pd-L1 Negative Tnbc by the National Medical Products Administration CI
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Key Product A400 Granted Fast Track Designation by the US Food and Drug Administration CI
Kelun-Biotech Shares Start Trading in Shanghai's Southbound Stock Connect MT
Kelun-Biotech Licensee Starts Phase 3 Trials for Cancer Treatment; Shares Rise 5% MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Collaboration with Merck Sharp & Dohme LLC CI
Kelun-Biotech Chosen as Constituent Stock of Hang Seng Indexes; Shares Fall 3% MT
Kelun-Biotech Controlling Shareholder Ups Stake; Shares Rise 4% MT
More news
1 day+2.48%
1 week-1.96%
Current month-1.96%
1 month+19.31%
3 months+93.89%
6 months+92.53%
Current year+60.35%
More quotes
1 week
153.90
Extreme 153.9
182.20
1 month
129.20
Extreme 129.2
182.20
Current year
63.65
Extreme 63.65
182.20
1 year
60.60
Extreme 60.6
182.20
3 years
60.60
Extreme 60.6
182.20
5 years
60.60
Extreme 60.6
182.20
10 years
60.60
Extreme 60.6
182.20
More quotes
Managers TitleAgeSince
Chief Executive Officer 51 21-02-07
Director of Finance/CFO 41 22-02-24
Chief Tech/Sci/R&D Officer 61 21-07-04
Members of the board TitleAgeSince
Founder 73 16-11-21
Director/Board Member 40 16-11-21
Director/Board Member 44 21-02-11
More insiders
Date Price Change Volume
24-05-08 165 +2.48% 1,672,300
24-05-07 161 -7.47% 374,300
24-05-06 174 +6.10% 321,856
24-05-03 164 -2.26% 84,900
24-05-02 167.8 -0.30% 123,170

Delayed Quote Hong Kong S.E., May 08, 2024 at 04:08 am EDT

More quotes
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd, formerly Sichuan Kelun Biotech Biopharmaceutical Co Ltd, is a China-based company mainly engaged in the research and development, production, and sales of drugs. The Company is mainly engaged in the research and development, production, and sales of biopharmaceuticals, chemical raw materials, and chemical drug formulations. The Company's products are mainly used for the treatment of breast cancer, non-small cell lung cancer, Gastrointestinal cancer and other non tumor diseases.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
165 HKD
Average target price
184 HKD
Spread / Average Target
+11.54%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW